Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

The term “disease of the mind” has significant implications in both medical and legal contexts. While it is often associated ...

Inc. (NASDAQ:MNMD – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $7.32, but opened at $7.15. Mind Medicine (MindMed) shares last traded ...

Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate LSD or the ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 8.3% during the third quarter, Holdings Channel reports.

Mescaline is under clinical development by Mind Medicine MindMed and currently in Phase I for Unspecified Psychiatric Disorders.